The Limited Times

Now you can see non-English news...

Covid-19: in the United States, the authorization of the Johnson & Johnson vaccine recommended by a scientific committee

2021-02-27T07:34:18.828Z


About twenty independent scientists have validated the use of the vaccine developed by the American pharmaceutical company Johnson & J


Soon a third vaccine on the American market?

A committee of twenty scientists recommends this Friday the authorization of the vaccine from the pharmaceutical group Johnson & Johnson in the United States.

A final green light must now come from the United States Medicines Agency, the FDA, but this news paves the way for the imminent distribution of several million doses of a third vaccine against Covid-19 in the country.

The team of experts, independent scientists, voted by voting that the benefits of the vaccine for people aged 18 and over outweighed the risks of its use.

Several mentioned, to justify their decision, the "race" against time induced by the pandemic, the lack of vaccine doses available and the appearance of new variants.

READ ALSO

> Johnson & Johnson's vaccine very effective against severe forms of Covid-19

The Johnson & Johnson vaccine, which can only be administered in a single dose and can be stored at refrigerator temperatures, is in this sense a major asset for optimizing the vaccination campaign.

Johnson & Johnson's vaccine conditional clearance is actually little doubt, as the FDA itself released a host of documents earlier this week in which it confirmed the vaccine's effectiveness.

Biden hails "a very safe and effective vaccine"

"The scans support a favorable safety profile without specific identified safety concerns that could prevent the issuance of an emergency use authorization," she wrote on Wednesday.

"If the FDA approves the authorization of this vaccine, we have a device to distribute it as quickly as Johnson & Johnson can," said US President Joe Biden on Thursday.

"We all saw the news about Johnson & Johnson's vaccine today - a safe and effective third vaccine," Joe Biden said from Houston on Friday, shortly after the committee vote.

We are going to use every avenue imaginable to expand the manufacture of the vaccine, the third vaccine, and get even more rapid progress ”in the vaccination campaign, added the US president.

READ ALSO

> Covid-19: follow the events of the day live

Morning essentials newsletter

A tour of the news to start the day

Subscribe to the newsletterAll newsletters

The effectiveness of the vaccine was, during trials, 85.9% against severe forms of Covid-19 in the United States.

All regions of the clinical trial combined, it was 66.1% against moderate forms of the disease, and overall “similar” for all categories of the population (ages, ethnicities).

The most frequently observed side effects were pain at the injection site, headache, fatigue and muscle pain.

The vaccine is already in use in South Africa, where a case of anaphylaxis - a severe allergic reaction - has been observed, Macaya Douoguih of Johnson & Johnson revealed during the meeting on Friday.

Such reactions, although very rare, have also been noted after injections of Moderna and Pfizer vaccines.

The effect of two doses instead of one under study

Representatives of the FDA also mentioned a few cases of urticaria and rare cases of thromboembolic events (obstruction of blood flow) and tinnitus, for which a link with vaccination cannot be excluded but which require further analysis. pushes to determine it.

The pharmaceutical company also said it is studying the effect of two doses - instead of one - on immune protection, which has raised concerns among experts, who fear that this could mislead the public or that 'He feels cheated if this option turns out to be more effective.

READ ALSO

> A temperature problem delays the delivery of AstraZeneca vaccines

At least three million doses of the "J&J" product are ready for distribution as early as "next week" according to the US government.

The American company has pledged to ship 100 million doses to the United States before the end of June.

Enough vaccines to immunize all Americans by the end of July

With 600 million doses ordered in total from Pfizer and Moderna, the United States will already have, by the end of July, enough vaccines to immunize almost the entire population.

But the addition of those from Johnson & Johnson could further accelerate the vaccination campaign.

In total, more than 70 million injections have already been carried out in the country, the country most bereaved by the pandemic.

So far, however, only 6.8% of Americans have received the two doses needed for maximum immunity conferred by the two already licensed vaccines, which use the innovative messenger RNA technique.

“J & J's” vaccine is a “viral vector” vaccine: it uses another low-virulent virus as a carrier, transformed to add genetic instructions from part of the virus responsible for Covid-19.

Once in the cells, a typical SARS-CoV-2 protein is produced, educating the immune system to recognize it.

Source: leparis

All life articles on 2021-02-27

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.